Health / WORLD

FDA seeks input on safeguards for early ibogaine trials

The agency is asking about trial design, dosing, safety monitoring and oversight, with comments due November 20.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

The FDA issued a request for information on how early-phase clinical trials of ibogaine products should be designed. It is seeking evidence and feedback on patient eligibility, dose escalation, care settings, stopping rules, safety monitoring and independent oversight.

The agency highlighted cardiac and neurologic risks and said a proposed starting dose should be supported by available evidence and not exceed 10 milligrams per kilogram. The request is for input on research design, not an approval of ibogaine treatment; the comment period is scheduled to close November 20, 2026.

Data

Timeline

FDA information request and comment timeline

The FDA information request and deadline stated in the release.

  1. · Occurred

    FDA information request issued

    Request for views and data on early ibogaine trial design.

  2. · Scheduled

    Comment period closes

    FDA says late comments will not be considered.

Methodology

The date and action are transcribed from FDA. The future deadline is source-stated and does not indicate a drug approval or trial result.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

  • United States · Place role: Coverage · Place type: Country or area · Location precision: Regional
    Evidence
    • Explicit preserved editorial country/region; no city or national centroid inferredwww.fda.gov ↗
Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

Three Riad’s Oliva products recalled over undeclared sesame

Oliva LLC announced on October 9 that it was recalling baba ghanouj, spicy baba ghanouj and hummus because sesame was not declared in the ingredient list. The U.S. Food and Drug Administration (FDA) posted the company notice the same day as a public service.

U.S. Food and Drug Administration (FDA)1 min read Data included
Health

Starfish cold-smoked seafood recalled over Listeria risk in the United States

Krasnyi Oktyabr Inc. voluntarily recalled its Starfish Seafood Trio of cold-smoked salmon, halibut and trout on October 9 because it may be contaminated with Listeria monocytogenes. The FDA posted the company announcement that day.

U.S. Food and Drug Administration (FDA)1 min read Data included